MBX Biosciences, Inc. SEC filings MBX

MBX Biosciences, Inc. has 232 filings in SEC EDGAR's recent list, going back to May 10, 2019. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (officer or director change). The company's fiscal year ends on December 31.

MBX Biosciences, Inc. SEC filings
Form Description Filed Period
EFFECT Filing Dec 8, 2025 —
CORRESP Letter to the SEC Dec 4, 2025 —
EFFECT Filing Sep 24, 2025 —
CORRESP Letter to the SEC Sep 22, 2025 —
CORRESP Letter to the SEC Sep 22, 2025 —
UPLOAD Letter from the SEC Aug 13, 2025 —
DRS Filing Aug 8, 2025 —
EFFECT Filing Sep 12, 2024 —
CERT Filing Sep 12, 2024 —
8-A12B Filing Sep 10, 2024 —
CORRESP Letter to the SEC Sep 10, 2024 —
CORRESP Letter to the SEC Sep 10, 2024 —
CORRESP Letter to the SEC Aug 30, 2024 —
UPLOAD Letter from the SEC Aug 30, 2024 —
CORRESP Letter to the SEC Aug 26, 2024 —
CORRESP Letter to the SEC Aug 23, 2024 —
UPLOAD Letter from the SEC Jul 22, 2024 —
DRSLTR Filing Jul 11, 2024 —
DRS/A Filing Jul 11, 2024 —
UPLOAD Letter from the SEC May 7, 2024 —
DRSLTR Filing Apr 26, 2024 —
DRS/A Filing Apr 26, 2024 —
UPLOAD Letter from the SEC Apr 17, 2024 —
DRS Filing Mar 22, 2024 —
D Filing Nov 18, 2022 —
D Filing Jul 27, 2020 —
D/A Filing May 10, 2019 —
D Filing May 10, 2019 —

Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MBX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Carmel, IN
SEC filer status
, Emerging growth company
SEC CIK
1776111

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.